Peptides Congress 2015

In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 20 speakers will present a full conference programme covering the topics outlined below. These topics have been compiled as a result of a comprehensive research process undertaken with our advisory board members including VPs, Directors, Senior Research Fellows and Professors from global pharmaceutical organisations and leading research institutions.

To view the agenda in full, please visit http://www.peptides-congress.com/download-agenda-marketing/

• Konrad Bleicher
  Peptide Area Head Discovery Chemistry, pRED, Roche Innovation Centre Basel
• Christophe Bonny
  Chief Scientific Officer, Bicycle Therapeutics Ltd
• Fabio Fais
  Principal Scientist, Novartis
• Paul Feldman
  Senior Vice President, EE DPU, RD Metabolic Pathways & Cardio Unit, GSK
• Torsten Hoffmann
  Executive Vice President and Chief Scientific Officer, Zealand Pharma
• Lutz Jermutus
  Senior Director, R&D, MedImmune
• Lyn Jones
  Head of Rare Diseases Chemistry, Head of Chemical Biology, Pfizer
• Aphrodite Kapurniotu
  Professor, Division of Peptide Biochemistry, TU München
• Daniel Kirchhofer
  Principal Scientist, Early Discovery Biochemistry, Genentech
• Tomas Landh
  Director, Strategy and Innovation Sourcing Diabetes Research Unit, Novo Nordisk
• Alastair Lawson
  Research Fellow & VP Structural Biology, UCB
• Alireza Manuchehri
  Director, Clinical Development, Eisai Ltd
• Gert Moll
  CSO, Lanthio Pharma
• Dinesh Patel
  President & CEO, Protagonist Therapeutics
• Joel Richard
  Joel Richard, Senior Vice President, Peptides – Head of CMCS Dreux Site, Ipsen
• Graham Simpson
  CPU Head, Peptides Chemistry, GlaxoSmithKline
• Michael Wagner
  Head of Peptides, Sanofi-Aventis
• Daniel Yin
  Principal Scientist, Parenteral Formulation Sciences, Merck